Group 1 - The core point of the article is that shareholder Zheng Anmin plans to reduce his stake in Haitai Xinguang by up to approximately 3.28 million shares, which represents no more than about 2.73% of the company's total share capital, within three months after the announcement [1] - Haitai Xinguang's revenue composition for the year 2024 is as follows: 77.94% from medical device manufacturing, 21.55% from the optical medical industry, and 0.51% from other businesses [1] - As of the report, Haitai Xinguang has a market capitalization of 6.1 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, indicating a hot secondary market in biomedicine [1] - There is a discussion about the cooling of fundraising in the primary market for biomedicine, despite the active secondary market [1]

Group 1 - The company HaiTai New Light (SH 688677) announced that as of the disclosure date, shareholder Ma Min directly holds approximately 1.01 million shares, accounting for 0.8409% of the total share capital [1] - Ma Min plans to reduce her holdings by no more than 250,000 shares, which represents no more than 0.2102% of the total share capital, through centralized bidding and block trading within three months after the announcement [1] - The company's major revenue composition for the year 2024 is projected to be 77.94% from medical device manufacturing, 21.55% from the optical medical industry, and 0.51% from other businesses [1] Group 2 - The market capitalization of HaiTai New Light is currently 5.7 billion yuan [2]